Definition, Quantification, and Utility of Biomarkers of Repetitive Brain Injury in Predicting Concussion and Other Long-Term Injury Risks in Patients With Atrial Fibrillation (Concussion AF)

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

July 15, 2017

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions
Cognitive Change
Interventions
OTHER

Biomarkers of Dementia and Cognitive Decline

"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~* Mini-Mental Status Evaluation~* Hachinski Ischemic Scale~* Cognitive Subscale of Alzheimer's Disease Assessment Scale~* Disability Assessment for dementia~* Quality of life improvement as assessed by:~ * Minnesota Living with Heart Failure Scale~ * Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"

Trial Locations (1)

84143

Intermountain Medical Center, Murray

All Listed Sponsors
lead

Intermountain Health Care, Inc.

OTHER

NCT03875131 - Definition, Quantification, and Utility of Biomarkers of Repetitive Brain Injury in Predicting Concussion and Other Long-Term Injury Risks in Patients With Atrial Fibrillation (Concussion AF) | Biotech Hunter | Biotech Hunter